Physician profile
Stephen Eisenbarth
NPI 1265662712
$1,928.16
in general payments reported to CMS, 2019-2025
14 companies · $573 in 2025
The $573 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $20.28 · 2022: $242 · 2023: $450 · 2024: $520 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.14 | 2022-2025 | |
| Oyster Point Pharma, INC. | $213.09 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $203.11 | 2019-2025 | Rocklatan |
| Mallinckrodt Hospital Products INC. | $187.32 | 2024-2025 | Acthar |
| Dompe US, INC. | $138.26 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $119.53 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $113.70 | 2025 | Xdemvy |
| Coopervision INC. | $93.87 | 2019 | |
| Biotissue Holdings INC. | $77.79 | 2023-2024 | |
| Sight Sciences, INC. | $73.34 | 2022-2025 | Omni Surgical System, Tearcare System |
| Bausch & Lomb Americas INC. | $60.41 | 2024-2025 | Miebo, Xiidra |
| Rxsight INC | $55.62 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Harrow Eye, LLC | $29.84 | 2024 | Iheezo |
| Novartis Pharmaceuticals Corporation | $14.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Eisenbarth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.